Our results open the door for enhancing personalized immunotherapy regimens through genomic profiling of AML patients, with the potential to extend the study cohort to better clarify the prognostic value of TRAIL/TNFSF10 rs12488654. This evidence concerns the gene TNFSF10 and acute myeloid leukemia.